Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer immunotherapy efficacy hinges on lymphocytes recognizing tumor antigens.
• Antigen identification is crucial for understanding immunotherapy response and developing better strategies.
• Next-generation sequencing enables identification of neoantigens (neoAgs) from mutations, driving new therapies.

Purpose of the Study:

• To review the role of neoantigens in cancer immunotherapies.
• To discuss strategies and results of neoantigen-based therapies.
• To describe non-classical tumor antigens and their identification methods.

Main Methods:

• Review of existing literature on tumor antigens and immunotherapies.
• Analysis of next-generation sequencing applications for neoantigen discovery.
• Description of methodologies for identifying non-classical tumor antigens.

Main Results:

• Neoantigens are increasingly important in various immunotherapies.
• Neoantigen-based strategies show promising results in cancer treatment.
• New methodologies are expanding the range of identifiable tumor antigens.

Conclusions:

• Understanding neoantigens and non-classical tumor antigens is key to advancing cancer immunotherapy.
• Improved antigen identification broadens the scope of targetable molecules for more effective cancer treatments.